Hepatic impairment No dose adjustment is necessary in sufferers with mild or reasonable (Child-Pugh A or B) hepatic impairment (see part 5.two). Exposure to midostaurin and its Lively metabolite CGP62221 is substantially decreased in sufferers with intense hepatic impairment than that in sufferers with ordinary hepatic perform (see portion 5. https://chamfortx863oty7.wikififfi.com/user